WEKO3
アイテム
Lenvatinib for Anaplastic Thyroid Cancer and Lenvatinib-Induced Thyroid Dysfunction
https://repository.lib.tottori-u.ac.jp/records/7191
https://repository.lib.tottori-u.ac.jp/records/7191f0e2d360-23ca-43a9-9ee6-339fb4fae0bd
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
etj7(3)_139.pdf (936.8 kB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2021-12-15 | |||||
| タイトル | ||||||
| タイトル | Lenvatinib for Anaplastic Thyroid Cancer and Lenvatinib-Induced Thyroid Dysfunction | |||||
| 言語 | en | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 主題 | Lenvatinib | |||||
| キーワード | ||||||
| 主題 | Anaplastic thyroid cancer | |||||
| キーワード | ||||||
| 主題 | Chemotherapy | |||||
| キーワード | ||||||
| 主題 | Hypothyroidism | |||||
| キーワード | ||||||
| 主題 | Tyrosine kinase inhibitor | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題 | Lenvatinib | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題 | Anaplastic thyroid cancer | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題 | Chemotherapy | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題 | Hypothyroidism | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題 | Tyrosine kinase inhibitor | |||||
| 資源タイプ | ||||||
| 資源タイプ | journal article | |||||
| 著者 |
小山, 哲史
× 小山, 哲史× 三宅, 成智× 藤原, 和典× 福原, 隆宏× Kitano, Hiroya× 竹内, 裕美× Morisaki, Tsuyoshi× Kitano, Hiroya |
|||||
| 著者所属（英） | ||||||
| 言語 | en | |||||
| 値 | Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine | |||||
| 著者所属（英） | ||||||
| 言語 | en | |||||
| 値 | Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine | |||||
| 著者所属（英） | ||||||
| 言語 | en | |||||
| 値 | Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine | |||||
| 著者所属（英） | ||||||
| 言語 | en | |||||
| 値 | Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine | |||||
| 著者所属（英） | ||||||
| 言語 | en | |||||
| 値 | Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine | |||||
| 著者所属（英） | ||||||
| 言語 | en | |||||
| 値 | Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine / Center for Head and Neck Surgery, Kusatsu General Hospital | |||||
| 著者所属（英） | ||||||
| 言語 | en | |||||
| 値 | Department of Otolaryngology Head and Neck Surgery, Tottori University Faculty of Medicine | |||||
| 抄録 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Background: Lenvatinib is an oral multitargeted tyrosine kinase inhibitor that has an anticancer action in patients with differentiated thyroid cancer that is refractory to radioiodine. Knowledge of the efficacy and safety of lenvatinib in patients with anaplastic thyroid cancer (ATC) is limited. Tyrosine kinase inhibitors frequently cause hypothyroidism; the incidence of hypothyroidism with lenvatinib is unclear. Objectives: We conducted a retrospective study to investigate the efficacy and safety of lenvatinib in ATC. Methods: Five patients with unresectable ATC were enrolled. Lenvatinib 24 mg once daily was administered until disease progression, unmanageable toxicity, withdrawal, or death occurred. We retrospectively analyzed objective response rate (ORR), time to progression (TTP), overall survival, and safety. Results: Three of the five patients (60%) had a partial response, and two (40%) had stable disease. ORR was 60%. Median TTP was 88 days, and overall survival was 165 days. Hypothyroidism was a common treatment-related adverse effect; four patients (80%) had hypothyroidism of any grade. These four patients had not undergone total thyroidectomy prior to lenvatinib administration, and the other patient had undergone total thyroidectomy. Treatment-related adverse effects of any grade were hypertension in 80% of patients, diarrhea in 40%, fatigue in 80%, and decreased appetite in 80%. Conclusions: Lenvatinib is an effective treatment and may improve the prognosis of unresectable ATC. Four of five patients had hypothyroidism, which may have been associated with treatment-induced injury of the thyroid gland. There were many treatment-related adverse effects, most of which were manageable by dose modification and medical therapy. | |||||
| 書誌情報 |
EUROPEAN THYROID JOURNAL en : EUROPEAN THYROID JOURNAL 巻 7, 号 3, p. 139-144, 発行日 2018-06 |
|||||
| 出版者 | ||||||
| 出版者 | S. Karger AG | |||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 22350640 | |||||
| DOI | ||||||
| 関連タイプ | isVersionOf | |||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | 10.1159/000485972 | |||||
| 権利 | ||||||
| 権利情報 | © 2018 European Thyroid Association Published by S. Karger AG, Basel. This is the peer-reviewed but unedited manuscript version of the following article: Eur Thyroid J 2018;7:139-144. (doi: 10.1159/000485972). The final, published version is available at | |||||
| 情報源 | ||||||
| 関連名称 | Koyama Satoshi, Miyake Naritomo, Fujiwara Kazunori, et al. Lenvatinib for Anaplastic Thyroid Cancer and Lenvatinib-Induced Thyroid Dysfunction. EUROPEAN THYROID JOURNAL. 2018. 7(3). 139-144. doi:10.1159/000485972 | |||||
| 関連サイト | ||||||
| 識別子タイプ | URI | |||||
| 関連識別子 | https://www.karger.com/Article/FullText/485972 | |||||
| 関連名称 | https://www.karger.com/Article/FullText/485972 | |||||
| 著者版フラグ | ||||||
| 出版タイプ | AM | |||||
| EISSN | ||||||
| 値 | 22350802 | |||||
